LPLaura Provenzi

Laura Provenzi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laura Provenzi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Ashok Kumar Shetty

    Institute for Regenerative Medicine, Department of Cell Biology and Genetics, School of Medicine, Texas A&M University Health Science Center, College Station, Texas, USA., College Station, TX USA

    1 shared publication
  • Daniel Rodrigo Marinowic

    Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil

    1 shared publication
  • Gabriele Zanirati

    Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre 90610-000, RS, Brazil

    1 shared publication
  • Isadora Machado Ghilardi

    Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil

    1 shared publication
  • Jaderson Costa da Costa

    Brain Institute (BraIns), Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil

    1 shared publication
  • Lucas Lobraico Libermann

    Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil

    1 shared publication

Latest Publications

  • Open Access

    Stem cell-based therapy for COVID-19 and ARDS: a systematic review

    by Gabriele Zanirati, Laura Provenzi, Lucas Lobraico Libermann, Sabrina Comin Bizotto, Isadora Machado Ghilardi, Daniel Rodrigo Marinowic, Ashok K. Shetty, Jaderson Costa Da Costa

    Despite global efforts to establish effective interventions for coronavirus disease 2019 (COVID-19) and its major complications, such as acute respiratory distress syndrome (ARDS), the treatment remains mainly supportive. Hence, identifying an effective and safe therapy for severe COVID-19 is critical for saving lives. A significant number of cell-based therapies have been through clinical investigation. In this study, we performed a systematic review of clinical studies investigating different types of stem cells as treatments for COVID-19 and ARDS to evaluate the safety and potential efficacy of cell therapy. The literature search was performed using PubMed, Embase, and Scopus. Among the 29 studies, there were eight case reports, five Phase I clinical trials, four pilot studies, two Phase II clinical trials, one cohort, and one case series. Among the clinical studies, 21 studies used cell therapy to treat COVID-19, while eight studies investigated cell therapy as a treatment for ARDS. Most of these (75%) used mesenchymal stem cells (MSCs) to treat COVID-19 and ARDS. Findings from the analyzed articles indicate a positive impact of stem cell therapy on crucial immunological and inflammatory processes that lead to lung injury in COVID-19 and ARDS patients. Additionally, among the studies, there were no reported deaths causally linked to cell therapy. In addition to standard care treatments concerning COVID-19 management, there has been supportive evidence towards adjuvant therapies to reduce mortality rates and improve recovery of care treatment. Therefore, MSCs treatment could be considered a potential candidate for adjuvant therapy in moderate-to-severe COVID-19 cases and compassionate use.